Kornimate/medical-research-clean huggingface dataset:
effects of imatinib in subjects with seasonal allergic rhinitis and who are sensitive to timothy grass pollen

Conditions: Seasonal Allergic Rhinitis

Summary: this study will assess the effects of imatinib on allergic inflammation following repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to timothy grass pollen.


Eligibility criteria:
inclusion criteria: * healthy male non-smoking subjects aged 18-55 years, with a history of seasonal allergic rhinitis consistent with timothy grass pollen allergy. they must show: a positive skin prick test to timothy grass pollen (wheal difference timothy grass pollen - negative control ≥ 3 mm) at or within the 12 months preceding the screening visit and demonstrate symptomatic worsening (tnss ≥4) within one hour after nasal allergen challenge * be otherwise healthy with no health problems that may jeopardize the subjects participating in the study, absence of history of other significant allergies. * subjects and their partners must agree to use effective contraceptive measures from screening until the end of study visit. exclusion criteria: * respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function. * structural nasal abnormalities or nasal polyps on examination, a history of frequent nose bleeding, recent nasal surgery or recent (within 8 weeks prior to baseline visit) or recent (four weeks) or ongoing upper or lower respiratory tract infection. * use of any medication that would affect the response to the allergen challenge (e.g. corticosteroids, decongestants, anti-histamines, medications with anti-inflammatory effects) or any other nasally applied medication within 14 days prior to allergen challenge (30 days for systemic anti-inflammatory therapy including oral corticosteroids), or known to influence imatinib bioavailability or clearance * history or laboratory evidence of acute or chronic renal insufficiency or abnormal liver function. * subjects may voluntarily withdraw from or be withdrawn from the study at the discretion of the investigator or the sponsor at any time. subjects may be withdrawn from the study prematurely for one of the following reasons: * subject withdrew consent * upper respiratory tract infection * presence of allergic rhinitis symptoms in the screening period or prior to pre-wash on day 1 * a past medical history of inherited heart disease, valve defect, cardiomyopathy, rheumatic fever, arrhythmias, cardiac interventions or clinically significant ecg abnormalities. * adverse events and non-tolerable symptoms resulting from allergen challenge * administration of a concomitant medication (other than those randomized to receive fluticasone propionate) that would impact on the study results (e.g. corticosteroids), including any subjects requiring asthma therapy (inhaled or systemic). other protocol-defined inclusion/exclusion criteria may apply

Keywords: imatinib, allergic inflammation, out of allergy season, repeated nasal allergen, seasonal allergic rhinitis, sensitive, timothy grass pollen, c-kit inhibition
addressing help-seeking barriers in developing an intensive treatment for veterans with panic disorder

Conditions: Panic Disorder

Summary: the purpose of this study is to understand some of the reasons why recently deployed veterans decline psychosocial treatment options for panic disorder and to test a brief weekend treatment for panic attacks.

the population of interest for this program includes men and women returning from deployment in iraq or afghanistan who are seen in the trp at the medvamc. the study consists of two parts: part 1 involves a qualitative investigation of treatment-seeking barriers specific to persons who refuse standard treatments and part 2 is a pilot intervention to treat panic symptoms in service members who have co-existing ptsd symptoms. part 1 will include approximately 15 individuals who will be interviewed by a member of the study staff. patients will be interviewed individually following a semi-structured questionnaire designed to help identify treatment-seeking barriers. part 2 will include 8 individuals who will be enrolled in an open-trial of a two-day intensive cognitive-behavioral treatment for panic disorder, which will occur over the weekend. no participants will be assigned to a control condition. all activities related to this project including the interviews and intervention will be delivered in either the trp at the medvamc or at the houston center for quality of care and utilization studies (hcqcus), a nearby facility.

Eligibility criteria:
inclusion criteria: 1. veterans; 2. age 18-74; 3. current diagnosis of panic disorder; 4. ptsd symptoms that either meet full diagnostic criteria from the diagnostic and statistical manual-fourth edition (dsm-iv) or are at a sub-clinical level. sub-clinical ptsd is defined as patients who meet either ptsd criteria b and c or b and d, but fail to meet all three; 5. panic disorder and ptsd present for at least 1 month; 6. part 1 only: patients who are clinically eligible to participate in the study and refuse standard psychosocial treatments (e.g., 12 weeks of cognitive behavioral therapy) for panic disorder. exclusion criteria: 1. current substance dependence; 2. diagnosed with bipolar disorder or psychosis; 3. current suicidal/homicidal ideation and intent; 4. severe depression (precluding participation in a research study); 5. panic attacks related only to a diagnosis of a specific phobia; 6. medical conditions mimicing anxiety (e.g., mitral valve prolapse); 7. part 1 only: patients who are clinically eligible for the study and are willing to engage in a minimum of 12 weeks of psychosocial treatment for panic disorder.
does weightbearing crutch technology impact patient compliance?

Conditions: Fracture Healing

Summary: the goal of this study is to determine if weight-bearing crutch technology that delivers active feedback to patients during their treatment will impact patient compliance with physician instructions.


Eligibility criteria:
inclusion criteria: * willing and able to participate in study and complete consent * will undergo treatment of an isolated tibial plateau, pilon, or ankle fracture and placed in a non-weightbearing status with the use of crutches at nyu. * have access and use of a mobile phone (exclusively ios and/or android devices) exclusion criteria: * patients with concomitant tbi * polytrauma patients * pathologic fractures * prisoners
chorioamnionitis and proinflammatory s100a12

Conditions: Chorioamnionitis Affecting Fetus or Newborn

Summary: histologic chorioamnionitis (hca) may lead to the fetal inflammatory response syndrome (firs) and increased levels of proinflammatory molecules.

histologic chorioamnionitis (hca) may lead to the fetal inflammatory response syndrome (firs). the aim of this pilot study was to evaluate s100a12, a marker of innate immune activation, in mothers with or without hca and in their infants. concentrations of s100a12, interleukin 6 (il-6) and c-reactive protein (crp) were evaluated in maternal, cord, and neonatal blood of very preterm infants. histologic examinations of placentae and umbilical cords were performed.

Eligibility criteria:
inclusion criteria: preterm birth exclusion criteria: congenital abnormalities

Keywords: neonate chorioamnionitis s100a12
anxiety and depression in copd; prevalence, detection and prognosis

Conditions: COPD; Anxiety Disorders; Depressive Disorder

Summary: the current cohort study of 300 stable copd patients aims to assess the following topics: * the prevalence of anxiety and depressive disorders in patients with copd * the screening properties of hospital anxiety and depression scale in patients with copd * the prognostic influence by anxiety or depressive symptoms and anxiety or depressive disorder. * whether characterization of 1) affective aspects of dyspnea symptoms or 2) persistent styles of thinking (worry or rumination) and metacognitions that drive these may improve the current recommendation of screening for anxiety and depression in copd in relation to its clinical relevance on functional status and three year outcome


Eligibility criteria:
inclusion criteria: * participant in in-hospital pulmonary rehabilitation at lhl-hospital gardermoen * diagnosis of copd exclusion criteria: * acute exacerbated phase of copd

Keywords: metacognitions hospital anxiety and depression scale
lipedema awareness in fibromyalgia

Conditions: Fibromyalgia; Lipedema

Summary: lipedema is a chronic debilitating condition that impacts the subcutaneous adipose tissue of the extremities. it is a chronic condition but should not be regarded as always progressing.the clinical course varies individually and is unpredictable. it may considerably diminish the patient's quality of life. fibromyalgia, similar to lipedema, is a debilitating chronic pain disease of unclear origin that primarily affects women. it is a complex syndrome marked by widespread pain and tenderness. fibromyalgia and lipedema are both marked by pain related to soft tissue. both disorders are not amenable to curative treatment, resulting in a significant burden on individual and public health. no definitive indicators, including abnormal laboratory or imaging results, can be discerned to differentiate one disorder from another. with this perspective, the aim of our study was to evaluate the presence of lipedema and lipedema-related factors in fibromyalgia patients.


Eligibility criteria:
inclusion criteria: * female patients * over the age of 18 * who met the fibromyalgia diagnostic criteria according to the american college of rheumatology (acr) 2016 fibromyalgia diagnostic criteria exclusion criteria: * renal or cardiac insufficiency, * the use of any drug that could influence body fluid and electrolyte balance, * the presence of a major somatic disease.

Keywords: fibromyalgia, lipedema, awareness
investigating hearing with ponto 3 superpower, a bone anchored hearing aid - investigating hear

Conditions: Hearing Loss, Conductive; Hearing Loss Mixed; Hearing Disability; Conductive Hearing Loss; Ear Diseases; Conductive Hearing Loss, Bilateral; Conductive Hearing Loss, Unilateral

Summary: the study is part of the post market clinical follow (pmcf) activity. the investigational device is the ce-marked ponto 3 superpower (available on the market since december 2016) already fitted to the subjects, and data is collected retrospectively from clinical routine visits. the study is a retrospective study. therefore there will be no study visits for treatment or follow-up in the study. subject inclusion for this clinical investigation will be performed among subjects who has been fitted with the ponto 3 superpower. to have a wide representative selection of subjects, enrollment will be spread over the 4 years since the device was available on the market since december 2016. the endpoints in the study will investigate the improvement of hearing with the ponto 3 superpower. the data will be collected from the subjects in the time period from the clinical routine visit where the ponto 3 superpower where fitted or just prior, and from the clinical routine visit following the fitting, where audiologic fitting follow-up procedures are performed (approximately 3 months).


Eligibility criteria:
inclusion criteria: 1. subjects who have consented to section 3 of the document: "gdpr - what this means to you" (appendix a) as part of a clinical routine visit. 2. fitted unilaterally or bilaterally with the ponto 3 superpower(s) on abutment(s) 3. adult subjects (18 years or older) 4. patient has attended a clinical routine visit where fitting of ponto 3 superpower has been performed and at least one following clinical routine visit where audiological measurements has been performed exclusion criteria: there are no exclusion criteria in this study due to the retrospective nature of the study. -
the effectiveness of music on pain during heel blood collection in premature infants

Conditions: Pain

Summary: premature babies receiving treatment and care in the neonatal intensive care unit (nicu) are exposed to various painful procedures. repetitive and untreated painful procedures have a negative impact on the physiological, cognitive and behavioral development of the baby. various approaches such as white noise, music, lullaby, kangaroo care, breastfeeding, swaddling, massage, and therapeutic positioning are used to reduce the painful processes that newborns are exposed to in the nicu.

premature babies receiving treatment and care in the neonatal intensive care unit (nicu) are exposed to various painful procedures. repetitive and untreated painful procedures have a negative impact on the physiological, cognitive and behavioral development of the baby. various approaches such as white noise, music, lullaby, kangaroo care, breastfeeding, swaddling, massage, and therapeutic positioning are used to reduce the painful processes that newborns are exposed to in the nicu.

Eligibility criteria:
inclusion criteria: * parent being voluntary to participate in the study * being born at 32-36+6 gestastional week * the baby's condition is stable * having passed hearing test * having not congenital malformation exclusion criteria: * birth weight below 2500 g * receiving analgesics or sedatives * need for mechanical ventilation * heel blood collection is not successful in the first time

Keywords: premature pain music
clinical observation of botulinum toxin a treatment in the treatment of rosacea

Conditions: Rosacea; Botulinum Toxin

Summary: the goal of this study is to study the clinical efficacy and safety of botox in the treatment of rosacea.

the main objective is to collect patients and then use different injection volumes of botulinum toxin intradermal injection for the treatment of rosacea erythema telangiectasia, and then to evaluate the clinical efficacy and safety of the treatment.

Eligibility criteria:
inclusion criteria * meeting the diagnostic criteria of mild to moderate erythema telangiectasis rosette acne; * more than 18 years old; * to obey the rules of the treatment in the study, and can be followed up for 12 weeks; * informed consent; exclusion criteria: * had received facial cosmetic surgery or botulinum toxin treatment within 6 months before this treatment; * due to systemic diseases such as autoimmune diseases or menopause facial flush; * had allergies botulinum toxin; * pregnant or breastfeeding; * other facial skin or oral disease therapy, including research before 4 weeks rose acne accept other treatment; * with basic neuromuscular diseases (such as myasthenia gravis, amyotrophic lateral sclerosis, etc.); * all landowners 4 weeks before the study whether any oral aminoglycoside drugs, benzodiazepines drugs or muscle relaxants; .was removed during treatment observation data is not complete, incomplete treatment and patients can't take medication as prescribed.
harp mindfulness study

Conditions: Cardiovascular Diseases

Summary: this study was designed using the multiphase optimization strategy (most) framework to determine whether two supplemental components increase the efficacy of a mindfulness-based cognitive therapy program delivered via telephone (mbct-t) for psychological distress. specifically, this study will test mindfulness booster sessions to follow a standard 8-week mbct-t intervention, as well as website support in patients with heart disease and/or heart disease risk factors.


Eligibility criteria:
inclusion criteria: * patients meeting one of the following criteria: * has a diagnosis of ischemic heart disease (icd-10 codes i20 - i25) with no cardiac hospitalizations in the past 6 months * has cardiovascular disease risk factors without meeting a diagnosis of ischemic heart disease or having a cardiovascular disease event (heart attack, stroke, heart failure, and/or unstable angina). cardiovascular disease risk factors include hypertensive diseases (icd-10 codes i10 - i11, i15 - i16), diabetes (e8 - e13), and/or hyperlipidemia (e78.0 - e78.5, e78.9) * patients meeting one or more of the following criteria at baseline: * elevated stress (pss-10 score ≥15) * mild to moderate depressive symptoms (phq-9 score between 5-14) * mild or greater anxiety (gad-7 score ≥5) * willing to provide informed consent and comply with all aspects of the protocol * able to read and communicate in english exclusion criteria: * active suicidal ideation * history of, or current diagnosis of, psychosis * significant cognitive impairment (noted in the ehr or evident during screening) * significant hearing loss * current participation in another behavioral clinical trial * has received the mbct-t intervention in a previous clinical trial.
by assessing the continuous respiratory physiological changes through prone position, determine the optimal duration for prone position

Conditions: Acute Respiratory Distress Syndrome; Prone Position; Electrical Impedance Tomography

Summary: the prone position leads to a more homogeneous distribution of ventilation by inflation of collapsed alveoli and reduction in alveolar hyperinflation. by employing eit, the study can obtain a thorough comprehension of the ongoing alterations in regional ventilation before and after adopting the prone position. it is also anticipated that there is an impact on inflammation biomarkers before and after the prone position. this assessment aids in determining the ideal duration for prone position therapy, encompassing the necessary hours and days in the prone position.

the prone position leads to a more homogeneous distribution of ventilation by inflation of collapsed alveoli and reduction in alveolar hyperinflation. by employing eit, the study can obtain a thorough comprehension of the ongoing alterations in regional ventilation before and after adopting the prone position. it is also anticipated that there is an impact on inflammation biomarkers before and after the prone position. this assessment aids in determining the ideal duration for prone position therapy, encompassing the necessary hours and days in the prone position. therefore, the investigators propose a project with the aim of collecting relevant clinical, laboratory, imaging, and respiratory physiology data from consenting patients with ards within the study period. the objective is to analyze changes in biomarkers following prone position.

Eligibility criteria:
inclusion criteria: 1. acute respiratory distress syndrome 2. age \> 18 3. serial arterial blood gas data：pao2/fio2 \ 0.6, peep\>5 cmh2o exclusion criteria: 1. implantable electronic devices (e.g., pacemakers) 2. body mass index \> 30 3. major thoracic and abdominal surgery 4. patients with unstable spine and pelvis conditions 5. pregnant women in the second and third trimesters 6. patients with head trauma, elevated intracranial pressure, or elevated intraocular pressure 7. hemodynamically unstable patients unsuitable for prone ventilation therapy 8. patients with active seizures
observational study to evaluate neurodevelopmental status in pediatric patients with hunter syndrome (mps ii)

Conditions: Mucopolysaccharidosis (MPS); Hunter Syndrome

Summary: hunter syndrome (mucopolysaccharidosis ii, \[mps ii\]) is a rare, genetically linked lysosomal storage disease (lsd) caused by deficiency of the enzyme, iduronate-2-sulfatase (i2s). most mps ii patients will present with some degree of neurodevelopmental involvement, ranging from severe cognitive impairment and behavioral problems to mildly impaired cognition. this is an observational study; no investigational treatment will be administered. the primary objective of this study is to evaluate the neurodevelopmental status of pediatric patients with mps ii over time and to gain information to guide future treatment studies in this patient population.


Eligibility criteria:
inclusion criteria: patients must meet all of the following criteria to be considered eligible for enrollment: 1. a. the patient has a deficiency in iduronate-2-sulfatase enzyme activity and b. the patient has a documented mutation in the iduronate-2-sulfatase gene. or c. the patient has a normal enzyme activity level of one other sulfatase 2. the patient is male, and is at least 2 years of age and less than 18 years of age at the time of informed consent. 3. the patient must have sufficient auditory capacity at enrollment, with or without hearing aids, in the investigator's judgment to complete the required protocol testing, and be compliant with wearing the aids on scheduled study visits. 4. the patient, patient's parent(s), or legally authorized guardian(s) has voluntarily signed an institutional review board / independent ethics committee-approved informed consent and/or assent form(s), as applicable. exclusion criteria: patients who meet any of the following criteria will be excluded from the study. 1. the patient has clinically significant non-hunter syndrome-related cns involvement or medical or psychiatric comorbidity(ies) which, in the investigator's judgment, may interfere with the accurate administration and interpretation of protocol assessments, affect study data, or confound the integrity of study results. 2. the patient has a general conceptual ability score (gca) or a developmental quotient on the cognitive scale below 55 at screening. 3. the patient is participating in an interventional clinical trial or has participated in an interventional clinical trial within 30 days prior to enrollment; participation in non interventional observational studies is permitted.

Keywords: neurodevelopmental status pediatric hunter syndrome patients central nervous system (cns) involvement observational study cognitive impairment
comparison of cnb and surgical specimens for er, pgr, her2 status and ki67 index in invasive breast cancer.

Conditions: Invasive Breast Cancer

Summary: * this is a prospective, single-center, non-randomized, non-controlled study. * the estrogen receptor (er), progesterone receptor (pgr), her2 status and ki67 index of cnb specimen are critical biomarkers for making neoadjuvant therapy strategy in invasive breast cancer. the concordance of these biomarkers between cnb and surgical specimen was varied in previous retrospective reports. the aim of this study is to determine the discordance of these biomarkers between cnb and surgical specimen and the influence of making treatment strategy by the discordance.


Eligibility criteria:
inclusion criteria: * • histologically confirmed primary invasive breast cancer by core needle biopsy exclusion criteria: * • pathological diagnosed ductal carcinoma in situ or microinvasive breast cancer by core needle biopsy * patient plans to receive neo-adjuvant system therapy